Roche and Flatiron Health Inc. announced today that the two partners have signed a definitive agreement under which Roche will acquire all shares of Flatiron Health, following on from an existing equity stake of 12.6%. The transaction is expected to close in the first half of 2018.
Bristol-Myers Squibb Co. and Nektar Therapeutics executed a global strategic development and commercialization collaboration for Nektar's lead immuno-oncology program, NKTR-214. Under the collaboration, the companies will jointly develop and commercialize NKTR-214 in combination with BMS's Opdivo (nivolumab) and Opdivo plus Yervoy (ipilimumab) in more than 20 indications across nine tumor types, as well as potential combinations with other anti-cancer agents from either of the respective companies and/or third parties.
The United Kingdom's National Institute for Health and Care Excellence has published a Final Appraisal Determination recommending FOTIVDA (tivozanib) for the first line treatment of adult patients with advanced renal cell carcinoma.
Guidelines developed collaboratively by the American Society of Clinical Oncology and the National Comprehensive Cancer Network offer clinicians recommendations for assessment and management of side effects related to immune checkpoint inhibitors.
Analysis of the phase II CONDOR trial indicates that the immune checkpoint inhibitor durvalumab is tolerable among heavily pre-treated patients with recurrent or metastatic head and neck cancer and has the potential to slow growth in tumors with low or negative expression of the PD-L1 protein.
A new study from the University of Wisconsin Carbone Cancer Center highlights a disparity in cancer care: the depressed spouses of cancer patients are 33 percent less likely to receive adequate treatment for depression than are patients whose spouses don't have cancer. Couples who live in rural areas are 72 percent less likely to receive recommended care for depression (including medication and talk therapy) than the depressed spouses of those without cancer.
The American Cancer Society started a grant program to support early career clinicians aiming to become clinician scientists.
The Department of Defense Ovarian Cancer Research Program has released a pre-announcement for FY 2018 funding opportunities. Program Announcements are anticipated to be posted on Grants.gov in March 2018. Clinical Development Award Must be an independent investigator at or above the level of Assistant Professor (or equivalent). Supports the translation of promising preclinical findings into... […]
The 2018 Szent-Györgyi Prize for Progress in Cancer Research will be awarded Douglas Lowy and John Schiller, of the NCI Center for Cancer Research for their contributions toward the development of vaccines for the human papillomavirus.
Kenneth Aldape joined the NCI Center for Cancer Research as chief of the Laboratory of Pathology.
